Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

13.29 +0.29 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows. Interesting Highlights: Marqeta (NASDAQ:MQ) was the largest company by market cap to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels
UniQure N.V. (NASDAQ: QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia B. Data... 
Via Benzinga
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition
UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged
The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,... 
Via Benzinga
Why Moderna, uniQure And Novavax Are Moving Today
Moderna, Inc. (NASDAQ: MRNA). uniQure N.V. (NASDAQ: QURE) and Novavax, Inc. (NASDAQ: NVAX) were among the biggest movers among biopharma stocks Thursday. Moderna Slides On Q1... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial... 
Via Benzinga
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug... 
Via Benzinga
Uniqure Stock Pops After FDA Says It Can Resume Gene Therapy Tests
The Food and Drug Administration said Monday that Uniqure can resume testing its hemophilia B gene therapy, and QURE stock popped. 
Via Investor's Business Daily
Exposures Product Safety
Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy
Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new... 
Via Benzinga
Exposures Product Safety
UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program
The FDA has removed the clinical hold on uniQure NV's (NASDAQ: QURE) hemophilia B gene therapy program after determining the company had... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares rose 13.81% to $10.96 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Advaxis... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.